Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

83.73 +0.11 (+0.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,108,413
Open 83.33
Bid (Size) 83.31 (1)
Ask (Size) 84.00 (1)
Prev. Close 83.62
Today's Range 83.11 - 83.97
52wk Range 57.16 - 89.74
Shares Outstanding 1,253,809,440
Dividend Yield 3.39%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
If You Invested $100 In This Stock 15 Years Ago, You Would Have $400 Today
 
Via Benzinga

Performance

YTD
-1.94%
-1.94%
1 Month
-1.79%
-1.79%
3 Month
+6.72%
+6.72%
6 Month
+40.49%
+40.49%
1 Year
+21.59%
+21.59%

More News

Read More
Could Gilead Sciences Stock Help You Become a Millionaire?
Via The Motley Fool
Mergers and Acquisitions in 2023 Off To A Strong Start
Via MarketBeat
Exposures Product Safety
16 Analysts Have This to Say About Gilead Sciences
Via Benzinga
Mount Gilead, NC Author Publishes Children's Book
Via PR Leap
If You Invested $100 In This Stock 15 Years Ago, You Would Have $400 Today
Via Benzinga
3 Smart Stocks to Buy if a Recession Is on the Way
Via The Motley Fool
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
From Gilead Sciences, Inc.
Via Business Wire
3 Stocks That Beat the S&P During the Great Recession
Via The Motley Fool
J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps
Via Talk Markets
This New Drug Could Be Gilead Sciences' Growth Catalyst
Via The Motley Fool
Cell and Gene Therapy Market Size, Share, Industry Analysis, Growth Estimates, Trends, Demand and Forecast 2022-2028
Via SBWire
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
2 Unstoppable Stocks That Could Beat the Market Again In 2023
Via The Motley Fool
Can The No. 1 Pharma Stock, Merck, Continue Its Blazing Run In 2023?
Via Investor's Business Daily
European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
From Gilead Sciences, Inc.
Via Business Wire
Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock?
Via The Motley Fool
FTX Exchange's Assets Worth $3.5B Held By Bahamian Regulators, Italy PM To Meet Intel Over Chip Investment, New Oral COVID Antiviral Might Be Better Than Pfizer's Paxlovid: Today's Top Stories
Via Benzinga
New Oral COVID-19 Antiviral Might Be Better Than Pfizer's Paxlovid With Faster Recovery, Fewer Side Effects, Data Shows
Via Benzinga
3 High-Yielding Dividend Stocks That Could See Hikes in January
Via The Motley Fool
Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program
Via Benzinga
Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?
Via InvestorPlace
Tesla, Apple, Lightjump, Southwest, Gilead: Why These 5 Stocks Are Drawing Investors' Attention Today
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.